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Resolution of acute inflammation is an active process essential for appropriate host responses, tissue protection and the return to homeostasis [1] [2] [3] . During resolution, specific omega-3 polyunsaturated fatty-acid-derived mediators are generated within resolving exudates, including resolvin E1 (RvE1) 4 and protectin D1 (PD1) 5 . It is thus important to pinpoint specific actions of RvE1 and PD1 in regulating tissue resolution. Here we report that RvE1 and PD1 in nanogram quantities promote phagocyte removal during acute inflammation by regulating leukocyte infiltration, increasing macrophage ingestion of apoptotic polymorphonuclear neutrophils in vivo and in vitro, and enhancing the appearance of phagocytes carrying engulfed zymosan in lymph nodes and spleen. In this tissue terrain, inhibition of either cyclooxygenase or lipoxygenases-pivotal enzymes in the temporal generation of both pro-inflammatory and pro-resolving mediators-caused a 'resolution deficit' that was rescued by RvE1, PD1 or aspirintriggered lipoxin A 4 analogue. Also, new resolution routes were identified that involve phagocytes traversing perinodal adipose tissues and non-apoptotic polymorphonuclear neutrophils carrying engulfed zymosan to lymph nodes. Together, these results identify new active components for postexudate resolution traffic, and demonstrate that RvE1 and PD1 are potent agonists for resolution of inflamed tissues.
Acute local inflammation in healthy individuals is self-limited and resolves by means of an active termination programme 1, 2 . Specialized chemical mediators are generated in this biochemically active process [4] [5] [6] [7] . Their complete stereochemical assignments were recently established and organic syntheses achieved [8] [9] [10] . These include arachidonic acid (AA)-derived lipoxin A 4 (LXA 4 ) and its epimer aspirintriggered LXA 4 8 , eicosapentaenoic acid (EPA)-derived RvE1 4, 9 , and docosahexaenoic acid (DHA)-derived PD1 (also known as neuroprotectin D1 when generated in neural tissues) 5, 10, 11 ( Fig. 1) . Recently, we assembled a 'resolution map' using lipidomics and proteomics to identify major cellular/molecular components, and introduced quantitative resolution indices 12 ( Supplementary Fig. 1 ). Each of these endogenous mediators elicits specific actions within resolution circuitry, giving precise quantitative changes in resolution indices 12 . The key histological event in tissue resolution is the loss of inflammatory polymorphonuclear neutrophils (PMNs) 13 . In a spontaneous resolving zymosan-initiated peritonitis, total leukocyte infiltration reached a maximum at ,12 h, and by 24 h had reduced by ,50% (ref. 12 ). Hence, 24 h post-zymosan is well within the classic resolution phase, and was selected to study the actions of RvE1 and PD1. When given together with zymosan, PD1 (300 ng, intraperitoneal) dramatically reduced PMN infiltration by .40% compared with mice challenged with zymosan alone ((6.7 6 0.1) 3 10 6 PMNs versus (11.6 6 1.0) 3 10 6 PMNs), illustrating potent anti-inflammation (Fig. 1a, left) . For comparison, equi-doses of aspirin-triggered lipoxin A 4 analogue (ATLa) gave ,26% PMN reduction, and RvE1 increased mononuclear infiltrates ,24%. These results indicate that each family of resolving mediators differentially affects the cellular composition of exudate. When ATLa, RvE1 and PD1 were given at the peak of inflammation (12 h after zymosan injection), each retained the ability to reduce PMN numbers at 24 h (Fig. 1a , right) and gave similar resolution intervals (Fig. 1b) , demonstrating their potent proresolving actions.
Inflammation resolution is a dynamic process, with cells being recruited to (influx) and cleared from (efflux) local inflamed sites. Reduction in exudate cells by these mediators could reflect their actions on anti-inflammation (reducing cell recruitment), proresolution (enhancing cell exit), or on both. Hence, it was important to determine whether these mediators directly activate specific resolution programmes. We evaluated whether RvE1 and PD1 affect macrophage ingestion of apoptotic PMNs in vivo-an essential part of the resolution orchestra in tissues 14 ( Fig. 2a) . Exudate cells collected at 24 h were labelled with FITC-conjugated anti-F4/80 Ab (a specific surface marker for mouse macrophages). Subsequently, cells were permeabilized to enable the labelling of ingested PMNs with phycoerythrin (PE)-conjugated anti-Gr-1 antibody (a specific surface marker for mouse PMNs). Mice treated with either ATLa or PD1 showed increased numbers of macrophages with ingested PMNs (cells with positive staining of both F4/80 and Gr-1 (F4/80 1 Gr-1 1 )), and thus demonstrated enhanced phagocytosis at 24 h (Fig. 2a) . ATLa, RvE1 or PD1 did not directly stimulate PMN apoptosis in vivo when given either at the initiation or at the peak of inflammation ( Supplementary Fig. 2 ). In contrast, when given at the peak of inflammation, cyclin-dependent kinase and specific ERK1/2 inhibitors enhance resolution by promoting PMN apoptosis 15, 16 ; this is accomplished by means of a different mechanism to that used by polyunsaturated fatty acid (PUFA)-derived endogenous mediators.
We also examined phagocytosis in vitro. Coincubation of elicited macrophages with apoptotic PMNs induced generation of endogenous LXA 4 (Fig. 2b, inset ), but not of pro-inflammatory leukotriene B 4 . LXA 4 peaked at 15 min during coincubations (20.7 6 2.6 pg per 0.2 ml, ,280 pM), identified by diagnostic ions in its tandem mass spectrometry (MS/MS) spectrum (Fig. 2b) . Macrophage phagocytosis was also apparent at 15 min, and gradually increased until 2 h. These findings indicated that, when ingested by macrophages, apoptotic PMNs rapidly initiated LXA 4 formation, which probably contributes to enhanced macrophage phagocytosis 17 at later intervals (30-120 min). Apoptotic Jurkat cells also stimulate LXA 4 formation during macrophage phagocytosis 18 . Of interest, during phagocytosis, PD1 was generated (23.2 6 2.1 pg ml -1 , ,70 pM); this was monitored by liquid chromatography (LC)-MS/MS (Supplementary Fig. 3 ). RvE1 was also formed by isolated cells in the presence of aspirin (,6 pg ml -1 , ,16 pM), and this level increased (,11 pg ml -1 , ,30 pM) with substrate EPA (Fig. 2b , MS/MS spectrum in Supplementary Fig. 3 ). Thus, LXA 4 , RvE1 and PD1 are produced when macrophages phagocytose apoptotic PMNs.
To investigate whether this set of proresolving mediators has a direct effect on isolated macrophages, macrophages were exposed to LXA 4 17 . LXA 4 , RvE1 and PD1 each regulated release of chemokines/cytokines during phagocytosis, reducing interferon-c and interleukin-6 (Fig. 2c) . In addition, LXA 4 increased anti-inflammatory interleukin-10. There were no apparent changes in levels of tumour necrosis factor-a, KC, JE and MIP-2 ( Supplementary Fig. 4 ). These results indicated that RvE1 and PD1 each promoted nonphlogistic macrophage engulfment of apoptotic PMNs. Taken together, it is now evident that LXA 4 , RvE1 and PD1 were generated in vitro (within 60 min) during macrophageapoptotic PMN interactions (Fig. 2b) . In turn, when macrophages were exposed to these mediators (20 min), they stimulated ingestion of apoptotic PMNs (Fig. 2c) . Glucocorticoid-stimulated phagocytosis of apoptotic PMNs requires much longer intervals (3-24 h) by comparison, and involves annexin I generation 19, 20 . The process of macrophage ingestion of apoptotic PMNs was recently termed 'efferocytosis' 21 Recognition of zymosan models recognition of microbes by the innate immune system 22 . LXA 4 , RvE1 or PD1 (100 nM), incubated with macrophages, stimulated uptake of zymosan 93 6 7%, 95 6 27% and 119 6 20%, respectively, compared with vehicle (Fig. 2d) . These mediators also enhanced macrophage uptake of non-opsonized latex beads, albeit to a much lesser extent (Fig. 2d) . Thus, in addition to apoptotic PMNs, LXA 4 , RvE1 and PD1 are potent stimulators of macrophage uptake of microbial particles-that is, opsonized zymosan.
We questioned whether these resolution agonists affect leukocyte traffic from zymosan-inflamed peritoneum by way of lymph nodes and spleen. In the resolution phase (24 h), the most pronounced locations of phagocytes carrying ingested zymosan (that is, leukocytes with engulfed zymosan, zymosan e leukocytes) were in the outer cortex of lymph nodes and in the spleen within the marginal zone surrounding white pulp (Fig. 3a) . ATLa (300 ng) increased zymosan e leukocytes in lymph nodes at 24 h (Fig. 3a) , giving .2-fold increase of total zymosan (0.23 6 0.03 versus 0.09 6 0.04 mg zymosan per mg protein in mice given zymosan alone) (Fig. 3b ). Significant increases in levels of zymosan in spleens were also observed. Passive efflux of nonengulfed zymosan was excluded, as significant extracellular association of zymosan was not apparent. Thus, total zymosan levels represent phagocytic leukocytes within lymph nodes and spleen. RvE1 also enhanced zymosan e leukocytes in both lymph nodes and spleen, with modest increases in lymph nodes compared with significant increases in the spleen. PD1-treated mice gave dramatic increases in zymosan levels of more than six-fold in lymph nodes and more than four-fold in the spleen. When ATLa, RvE1 or PD1 were each given at the peak of inflammation, they also enhanced, to a lesser extent, zymosan e leukocytes in lymph nodes and spleen (Fig. 3b) . Thus, LXA 4 , RvE1 and PD1 are biosynthesized in inflammatory exudates 12 ( Supplementary Fig. 5 ), and, when these mediators were added back, they promoted phagocyte removal of microbial challenge by way of lymphatics. It is noteworthy that their precursors (AA, EPA and DHA) were also elevated during peritonitis 12 (Supplementary Fig 5) .
Next we investigated whether disruption of biosynthetic pathways of these mediators altered resolution. In the biosynthesis of aspirintriggered LXA 4 and RvE1, acetylated cyclooxygenase (COX)-2 is pivotal 4, 8 ( Supplementary Fig. 6 ). Pharmacologic inhibition of COX-2 delays resolution 23 . In peritoneal leukocytes, COX-2 was induced within 4 h after zymosan challenge and remained elevated until 72 h (not shown). COX-2 inhibition by NS-398 (10 mM) decreased macrophage phagocytosis of apoptotic PMNs in vitro, and reduced prostaglandin E 2 and LXA 4 ( Supplementary Fig. 7 ). Lipoxygenases (LOX) are also essential in biosynthesis of PUFA-derived mediators 4, 5, 8, 24 . LOX inhibition by baicalein 25 (10 mM) impaired macrophage phagocytosis and reduced LXA 4 , 15-hydroxyeicosatetraenoic acid (15-HETE) and 12-HETE, as well as 17-hydroxy-docosa-4Z,7Z,10Z,13Z,15E,19Z-hexaenoic acid (17-HDHA)-a marker of PD1 biosynthesis (Supplementary Fig. 7 ). Thus, reduction in protective mediators (for example, LXA 4 ) could reflect hampered phagocytosis when COX and LOX inhibitors were present.
During peritonitis, COX inhibition by NS-398 (ref. 23 ; 100 mg) increased exudate leukocytes by ,22% and PMNs by ,41% at 24 h (Fig. 3c and Supplementary Table 1 ). In addition, zymosan amounts in both lymph nodes and spleen were significantly reduced by .50%, indicating impaired resolution. When ATLa, RvE1 or PD1 (300 ng) was administered along with a COX-2 inhibitor, each markedly reduced exudate leukocytes and increased zymosan amounts in lymphatics to levels comparable to those in zymosan-challenged mice (Fig. 3c) . The LOX inhibitor (100 mg) gave similar results ( Fig. 3d and Supplementary Table 1) . Hence, disrupting biosynthesis of these protective mediators with either COX-2 or LOX inhibitors caused a 'resolution deficit' phenotype, blocking phagocytic removal To further study phagocytes leaving the inflamed peritoneum, mice were injected with fluorescein isothiocyanate (FITC)-labelled zymosan. As early as 4 h, we found leukocytes carrying FITCzymosan (FITC-zymosan e leukocytes) beginning to appear in the perinodal adipose tissue (12 6 5 FITC-zymosan e leukocytes per high power field (HPF), Fig. 4A and 4Bc-f) , indicating that exiting leukocyte traffic from the inflamed site started early, namely during the acute inflammatory phase. In contrast, few FITC-zymosan e leukocytes were noted in lymph nodes, and none were apparent in spleen. With progression of resolution at 24 h, FITC-zymosan e leukocytes increased .2-fold in perinodal adipose tissue, with the highest numbers in lymph nodes (,50 FITC-zymosan e leukocytes/HPF); they also appeared within the spleen. In lymph nodes, a small population of FITC-zymosan e leukocytes observed within cortex areas were PMNs (,10%) (Fig. 4Bg-i) , indicating that these PMNs were phagocytically active, directly transporting zymosan to lymph nodes before their apoptosis and later engulfment by macrophages. Some of the FITC-zymosan e leukocytes displayed dendritic cell-like morphology with characteristic fine cellular protrusions within afferent lymph vessels (Fig. 4Bj) and spleen (Fig. 4Bk, l) .
The widely appreciated exit routes of leukocytes from inflamed peritoneum involve drainage by means of afferent lymph vessels into lymph nodes (lymphatic) and subsequently into the spleen (humoral) 13 ( Supplementary Fig. 9 ). In addition to these, we identified high numbers of FITC-zymosan e leukocytes extravasating from the afferent lymph vessels into perinodal adipose tissue before reaching lymph nodes (subcapsular sinus; Fig. 4Bc-f) . We termed this process 'lipopassage', because it is a new trafficking route for leukocytes to exit exudates. Macrophage efflux from the peritoneum into lymphatics is dependent on different adhesion molecules, such as b1-integrin 26 and Mac-1 (also known as CD11b/CD18) 27 . CD18 is involved in LXA 4 -stimulated macrophage phagocytosis of apoptotic PMNs 17 . Hence, it is likely that adhesion molecules play a role in lipopassage. Adipocytes are anatomically associated with lymph nodes and might be involved in modulating inflammation 28 . Our present findings provide a potential link between perinodal adipose tissue and phagocyte removal from exudates during resolution. In addition, nonapoptotic PMNs carrying zymosan exit exudates, providing evidence that PMNs themselves actively contribute to resolution of inflammation, along with macrophages. Thus, disease processes recently linked to inflammation (for example, diabetes and obesity) 29 might involve resolution deficits as part of their pathogenesis.
Here we demonstrate novel protective actions for RvE1 and PD1 in promoting resolution following microbial challenge, as evidenced by their regulating leukocyte infiltration, stimulating macrophage phagocytosis of apoptotic PMNs, and increasing phagocytes carrying zymosan in lymph nodes and spleen ( Supplementary Fig. 10 ). These potent 'resolution agonists' orchestrate the return of the tissue to homeostasis and are able to rescue resolution deficits emplaced by pharmacological inhibitors of COX and LOX. Together, these results emphasize that resolution agonists (for example, RvE1 and PD1) and resolution programmes might have therapeutic potential when sustained inflammation and/or impaired resolution are components of pathophysiology.
METHODS SUMMARY
Murine peritonitis. FVB mice were given lipid mediators (300 ng) at the same time as or 12 h after zymosan A (1 mg ml -1 ; Sigma) by intraperitoneal injection. A COX-2 inhibitor (NS-398; Cayman Chemicals) or LOX inhibitor (baicalein; Sigma) was given (100 mg) 30 min before zymosan challenge. Phagocytosis and apoptosis. For PMN apoptosis, exudate cells were labelled with FITC-conjugated anti-annexin-V antibody and PE-conjugated anti-mouse Gr-1 antibody (eBioscience). For phagocytosis in vivo, exudate cells were labelled with FITC-conjugated anti-mouse F4/80 antibody, permeabilized with 0.1% Triton X-100, and then labelled with PE-anti-Gr-1 antibody. For phagocytosis in vitro, aged PMNs were labelled with PE-anti-Gr-1 antibody. Elicited macrophages were incubated with lipid mediators. PE-anti-Gr-1 antibody-labelled PMNs were then coincubated with treated macrophages at a 2:1 ratio. In separate experiments, fluorescent-labelled zymosan or latex particles (Molecular Probes) were added to treated macrophages at a 10:1 ratio. Macrophages were then labelled with FITC-anti-F4/80 antibody and monitored by flow cytometry. Mediator lipidomics. Mass spectral analyses were performed using a Qstar XL Hybrid LC/MS/MS system equipped with a Turbospray ion source (Applied Biosystems) and operated in negative electrospray mode. Zymosan quantitation. Inguinal lymph nodes and spleens from zymosaninjected mice were harvested, zymosan was extracted by homogenization and sonication, and supernatants were collected. For zymosan quantitation, 96-well plates were pre-coated with anti-zymosan IgG (Molecular Probes), followed by addition of FITC-zymosan and supernatants containing zymosan. Fluorescence was monitored by fluorometry. Immunohistochemistry. Immunohistology slides prepared from paraffinembedded sections were incubated with either rabbit anti-zymosan antibody (Molecular Probes) or rabbit anti-FITC antibody (Dako), followed by biotinylated swine anti-rabbit IgG and peroxidase-conjugated streptavidin-biotin complex (Dako). The bound peroxidase was visualized with diaminobenzidine (brown precipitate). Zymosan-containing cells were determined by counting in ten high-power fields (3200). Statistics. Results are expressed as mean 6 standard error of mean (s.e.m.). Group comparisons were carried out using one-way analysis of variance or Student's t-test, with P values #0.05 taken as statistically significant. 
METHODS
Murine peritonitis. Male FVB mice (6-8 weeks; Charles River) were anaesthetized with isoflurane. Zymosan A (1 mg ml -1 , Sigma) was administered intraperitoneally alone or with specific lipid mediators (ATLa, RvE1 or PD1, 300 ng per mouse or ,12 mg kg -1 , intraperitoneal) for these experiments. In separate groups, ATLa, RvE1 or PD1 was given 12 h after zymosan injection. ATLa, RvE1 and PD1 were prepared by total organic synthesis in the Organic Synthesis Core of the Specialized Center for Research by N. Petasis [8] [9] [10] in accordance with recently published physical and biological criteria. In the case of COX-2 inhibitor (NS-398, Cayman Chemicals) and LOX inhibitor (baicalein, Sigma), each was given at 100 mg per mouse (or ,4 mg kg 1 Gr-1 1 macrophages were evaluated using FACsort software gated for 10,000 events.
For determining macrophage phagocytosis of zymosan (Texas red-labelled, Molecular Probes) or latex (Fluo Spheres carboxylate-modified microspheres, 1.0 mm, orange fluorescent; Molecular Probes), elicited macrophages were collected after 72 h peritonitis and incubated with lipid mediators (LXA 4 , RvE1 or PD1, 100 nM) or vehicle alone for 20 min. Zymosan or latex particles were then incubated with previously treated macrophages at a 10:1 ratio for 60 min. Macrophages were collected and labelled with FITC-conjugated anti-mouse F4/ 80 antibody. F4/80 1 zymosan 1 or F4/80 1 latex 1 macrophages were evaluated using FACsort software gated for 10,000 events. Mediator lipidomics. Samples were extracted with deuterium-labelled internal standards (1-2 ng deuterium-labelled PGE 2 and 0.4 ng deuterium-labelled PD1) using C18 solid phase extraction (Alltech Associates). For LC-MS/MS analysis, an Applied Biosystems Qstar XL was used, equipped with a LUNA C18-2 (100 mm 3 2 mm 3 5 mm; Phenomenex) column. High-performance liquid chromatography conditions: 0-8 min, 50% A, 50% B; 8-30 min, 100% B (A, 0.01% acetic acid; B, acetonitrile:methanol:acetic acid 50:50:0.01%), flow rate 0.2 ml min -1 , UV 190-400 nm. All mass spectral analyses were performed using a Qstar XL equipped with a Turbospray ion source (Applied Biosystems) and operated in negative electrospray mode. Parameters for TOF mass scan and product ion scans were: Cur, 30 p.s.i.; GS1, 40 p.s.i.; GS2, 50 p.s.i.; CAD 5; TEM, 400 uC; DP, -50 V; FP, -220; DP2, -10; ISV, -4,200. Q1 resolution unit. The voltage used for collisional activated dissociation varied according to molecular species and ranged from -20 V to -30 V for product ion scan. A mixture of synthetic 15-, 12-, 5-HETE, LXA 4 , RvE1, 17S-HDHA and PD1 was used to obtain standard curves for each compound. Linear regression gave R 2 values of .0.99 for each. In some experiments, LXA 4 and LTB 4 formation were also determined by ELISA (Neogen). Quantitation of zymosan A particles. Inguinal lymph nodes and spleens were collected (24 h after zymosan injection), and dried in an oven (60 uC). Dried tissues were pulverized mechanically, resuspended in 50 mM PBS with 1% Triton-X, and homogenized, followed by sonication and three cycles of freezethaw. Samples were centrifuged, supernatants collected and total protein amounts determined using Bio-Rad protein assay (Bio-Rad). For zymosan quantitation, polystyrene 96-well plates were precoated with rabbit anti-zymosan IgG (1 mg per well, Molecular Probes). The competitive assay was initiated by adding FITC-zymosan (0.5 mg 50 ml ) or samples (50 ml) into each well. After incubation for 2 h at room temperature and three washings with wash buffer, fluorescence was then determined by a fluorometer. All samples were assayed in triplicate, and zymosan levels were normalized by either dry tissue weight or total protein amounts in each sample. Immunohistochemistry. Inguinal lymph nodes, corresponding afferent lymph vessels, and perinodal adipose tissues were excised 4 and 24 h following zymosan or FITC-zymosan challenge. Slides for immunohistology were prepared for a service fee by the Specialized Histopathology Core Laboratory, Department of Pathology, Brigham and Women's Hospital, Boston, USA. After formaldehyde fixation and paraffin-embedding, sections were incubated with the primary rabbit anti-zymosan antibody (Molecular Probes, 1:500) or rabbit anti-FITC antibody (Dako) overnight at 4 uC. Specific binding of the antibody was detected with a secondary biotinylated swine anti-rabbit IgG F(ab)2 fragment (1:400, 30 min, Dako), followed by incubation with a peroxidase-conjugated streptavidin-biotin complex (Dako). The bound peroxidase was then visualized with diaminobenzidine as a chromogen (brown precipitate). Sections were counterstained with Mayer's Hemalaun. Negative controls consisted of sections incubated in the absence of the primary antibody. The number of cells with engulfed FITC-zymosan in the perinodal adipose tissue, lymph nodes and spleen was determined by counting in 10 HPFs (3200 magnification). Statistics. All results were calculated and expressed as mean 6 s.e.m. Group comparisons were carried out using one-way analysis of variance or Student's t-test where appropriate, with P values # 0.05 taken as statistically significant (sufficient to reject the null hypothesis).
